Tag Archives: pre-seed

Hot Investor Mandate: Newly Established VC Fund Invests in Innovative Digital Health and Medtech/Diagnostics Technologies with Software Components

12 Jul

A new venture fund started investing in pre-seed, seed and Series A rounds. The firm’s main investment areas are in companies that advance and improve human health through novel models of care delivery and in companies that are at the cutting-edge of frontier technology, such as neurotech, brain/machine interfaces, genomics and AI. The firm will consider digital health companies as well as diagnostics and medical device companies, as long as they have a software component. The firm will only invest in companies with disruptive technology, not incremental innovations. The firm will invest between $.1-1.5M in the initial investment, with the possibility of participating in following rounds. The firm is willing to lead or co-invest, has made 7 investments to date and is looking to invest in 4-6 companies a year.

The firm will consider digital health companies that are focused on improving patient care. Ideally, companies will already have a pilot with some outcomes-based data indicating traction. The firm is also interested in medical device companies, but will only invest if there is a significant software and/or radical innovation component. The firm will also consider diagnostics, such as genomics-based technologies, but not in vitro diagnostics. The firm will not invest in traditional therapeutics (i.e. small molecule or biologics) companies but will consider software-as-medicine and bioelectronic medicine.

Due to the firm’s preference for cutting-edge technology, the firm prefers that there be at least one technical expert in the company leadership. If acting as a lead investor, the firm will take a board or board observer seat. The firm prefers to be an active investor, providing multi-faceted support to portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Life Science Investor Mandate 2: CVC of Large Pharma Looking Opportunistically for Life Science Investments

17 Jul

The Corporate Venture Capital arm of a Global Pharmaceutical company provides seed and venture capital to development stage companies within life science and biotechnology. The firm provides pre-seed grants and seed investments to early-stage life science projects in Scandinavia. The firm’s venture investment activities are structured as an open evergreen fund. The firm invests at any stage of development – seed, venture, and growth. The firm also makes late-stage investments in public/private companies with a positive cash flow. The firm can allocate up to $30M per company, but generally allocates between $5M to $20M. The firm seeks companies that are based in North America and Europe. The firm has no current mandate for the number of allocations it plans to make and will evaluate relevant opportunities as they surface.

The firm is opportunistic in the life sciences space. The firm specifically focuses on companies that specialize in the development of novel drugs, new procedures for diagnosis and control of diseases, development of medical devices and instruments, and industrial biotechnology.  The firm is open to all technology and indication areas within these sectors. 

The firm seeks company ownership in return for its seed investments and influential equity ownership for late-stage investments. The firm considers both pre-revenue and revenue generating private and public companies.  The firm is generally opportunistic with the management team, but highly prefers an experienced and qualified management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

%d bloggers like this: